- Home
- PHAR vs BHK Comparison
PHAR vs BHK Comparison
Compare PHAR & BHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- BHK
- Stock Information
- Founded
- PHAR 1988
- BHK 2001
- Country
- PHAR Netherlands
- BHK United States
- Employees
- PHAR N/A
- BHK N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- BHK Finance Companies
- Sector
- PHAR Health Care
- BHK Finance
- Exchange
- PHAR Nasdaq
- BHK Nasdaq
- Market Cap
- PHAR 731.1M
- BHK 704.2M
- IPO Year
- PHAR N/A
- BHK N/A
- Fundamental
- Price
- PHAR $10.00
- BHK $9.61
- Analyst Decision
- PHAR Strong Buy
- BHK
- Analyst Count
- PHAR 3
- BHK 0
- Target Price
- PHAR $30.00
- BHK N/A
- AVG Volume (30 Days)
- PHAR 3.6K
- BHK 188.3K
- Earning Date
- PHAR 07-31-2025
- BHK 01-01-0001
- Dividend Yield
- PHAR N/A
- BHK 8.34%
- EPS Growth
- PHAR N/A
- BHK N/A
- EPS
- PHAR N/A
- BHK 1.03
- Revenue
- PHAR $320,708,000.00
- BHK N/A
- Revenue This Year
- PHAR $13.31
- BHK N/A
- Revenue Next Year
- PHAR $7.68
- BHK N/A
- P/E Ratio
- PHAR N/A
- BHK $10.42
- Revenue Growth
- PHAR 24.13
- BHK N/A
- 52 Week Low
- PHAR $6.65
- BHK $9.02
- 52 Week High
- PHAR $12.61
- BHK $11.09
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- BHK 38.85
- Support Level
- PHAR $9.99
- BHK $9.60
- Resistance Level
- PHAR $10.59
- BHK $9.73
- Average True Range (ATR)
- PHAR 0.35
- BHK 0.08
- MACD
- PHAR -0.14
- BHK 0.01
- Stochastic Oscillator
- PHAR 7.45
- BHK 10.53
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About BHK Blackrock Core Bond Trust
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its managed assets in bonds that are investment-grade quality at the time of investment. The trust's investments will include a broad range of bonds, including corporate bonds, U.S. government and agency securities and mortgage-related securities.